
BMEA Stock Forecast & Price Target
BMEA Analyst Ratings
Bulls say
Biomea Fusion is a promising clinical stage diabetes and obesity medicines company with a positive outlook due to its two main drug candidate programs: icovamenib, a selective inhibitor of menin, and BMF-650, a next-generation GLP-1 receptor agonist. Icovamenib has shown effectiveness in improving insulin secretion and A1c levels in clinical trials, with potential launch in 2030 for a large market opportunity. The company is also addressing financial risks and has a potential disease-modifying treatment in a competitive market.
Bears say
Biomea Fusion is a clinical-stage biotech company focused on developing small molecule drugs for diabetes and obesity. However, while its lead candidate, icovamenib, has shown promising results in early trials, the drug's effectiveness has yet to be confirmed in larger patient populations and its mechanism of action may be sensitive to patient selection and other factors. Additionally, the company faces competition from established diabetes and obesity treatments, which may limit the commercial potential of its drugs.
This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.
BMEA Analyst Forecast & Price Prediction
Start investing in BMEA
Order type
Buy in
Order amount
Est. shares
0 shares